Grifols (GRFS) Goodwill & Intangibles (2009 - 2025)
Grifols (GRFS) posted Goodwill & Intangibles of $11.1 billion for Q4 2025, up 0.83% quarter-over-quarter from $11.0 billion in Q4 2024, and up 0.83% year-on-year from $11.0 billion in Q4 2024.
Grifols (GRFS) Goodwill & Intangibles (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Goodwill & Intangibles for 16 consecutive years, with $11.1 billion the latest figure, recorded in Q4 2025.
- Goodwill & Intangibles for Q4 2025 came in at $11.1 billion, up 0.83% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.1 billion (up 0.83% YoY), and the FY2025 annual result was $11.1 billion, up 0.83% from the prior year.
- Goodwill & Intangibles was $11.1 billion for Q4 2025 at Grifols, up from $11.0 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $11.1 billion in Q4 2025 and troughed at $7.4 billion in Q4 2023.
- Average Goodwill & Intangibles over 5 years is $9.8 billion, with a median of $10.2 billion recorded in 2022.
- Year-over-year, Goodwill & Intangibles decreased 26.75% in 2023 and surged 48.27% in 2024.
- Over 5 years, Goodwill & Intangibles stood at $9.0 billion in 2021, then gained by 12.94% to $10.2 billion in 2022, then fell by 26.75% to $7.4 billion in 2023, then soared by 48.27% to $11.0 billion in 2024, then climbed by 0.83% to $11.1 billion in 2025.
- Per Business Quant data, the three most recent Goodwill & Intangibles figures were $11.1 billion in Q4 2025, $11.0 billion in Q4 2024, and $7.4 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.13 Bn |
| Dec 31, 2024 | 11.04 Bn |
| Dec 31, 2023 | 7.44 Bn |
| Dec 31, 2022 | 10.16 Bn |
| Dec 31, 2021 | 9.00 Bn |
| Dec 31, 2020 | 8.21 Bn |
| Sep 30, 2020 | 8.95 Bn |
| Mar 31, 2020 | 8.61 Bn |
| Dec 31, 2019 | 8.46 Bn |
| Sep 30, 2019 | 8.77 Bn |
| Mar 31, 2019 | 8.43 Bn |
| Dec 31, 2018 | 7.53 Bn |
| Sep 30, 2018 | 7.65 Bn |
| Mar 31, 2018 | 7.11 Bn |
| Dec 31, 2017 | 6.90 Bn |
| Dec 31, 2016 | 5.23 Bn |
| Dec 31, 2015 | 5.15 Bn |
| Dec 31, 2014 | 5.30 Bn |
| Dec 31, 2013 | 3.78 Bn |
| Sep 30, 2013 | 3.75 Bn |